U.s. food and drug administration accepts new drug application for review, grants priority review for takeda's tak-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that the united states (u.s.) food and drug administration (fda) has accepted for review the company's new drug application (nda) and granted priority review for the investigational therapy budesonide oral suspension, tak-721, which has been designed specifically for eosinophilic esophagitis (eoe).1 if approved, tak-721 will be the first fda-approved treatment for the chronic infl
TAK Ratings Summary
TAK Quant Ranking